The rising prevalence of Autism Spectrum Disorder to boost Autism Spectrum Disorder Therapeutics Market growth

Autism Spectrum Disorder Therapeutics 

Autism Spectrum Disorder Therapeutics Market Size, Share & Trends Analysis Report By Treatment Type (Stimulants, Antipsychotic Drugs), and by Region (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) - Outlook, Size, Share and Opportunity Analysis 2023 – 2030

The global Autism Spectrum Disorder Therapeutics Market is estimated to be valued at US$ 2.05 billion in 2022 and is expected to exhibit a CAGR of 6.1 % over the forecast period, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Autism Spectrum Disorder is a situation that is linked to the development of the brain that affects how a person receives things and interacts with others, the problems in social communication, and the active participation of a person in society. Autism Spectrum Disorder Therapeutics also comprises of restricted and repetitive methods of behavior such as anger. Autism Disorder Treatment comprises the situations that were earlier regarded as Asperger’s syndrome, an unclear method of the pervasive growth ailment. Few people still utilize the word Asperger’s syndrome in which is usually thought to be a very slight end of the Autism Disorder Treatment.

Competitive Landscape:

Key players involved in the growth of global Autism Spectrum Disorder Therapeutics Market are Curemark LLC, Johnson & Johnson Services Inc., Axial Therapeutics Inc., Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Merck & Co., Inc., Yamo Pharmaceuticals, Novartis AG and Pfizer Inc.

Market Key Drivers:

The rising prevalence of Autism Spectrum Disorder is expected to drive the growth of the global Autism Spectrum Disorder Therapeutics Market. For instance, as per CDC around 1 in every 44 children suffer from Autism Spectrum Disorder.

The rising R&D of new medications to cure the disease in patients in projected to fuel the growth of the global Autism Spectrum Disorder Therapeutics Market. For instance, in July 2022, AbbVie Inc. and Otsuka Pharmaceutical Co., Ltd. conducted a trial on phase II of the medicine Vraylar and Rexulti respectively, in patients suffering from autism.

Covid-19 Impact Analysis:

The Covid-19 outbreak has adversely affected the growth of global Autism Spectrum Disorder Therapeutics Market due to the rise in surge of pandemic.  The rising cases has led to the shift of physicians from treating other disorder towards curing Covid-19 patients. The lack of physicians, shortage of beds and the delay in treatment of others disorders in the healthcare system have impeded market growth.

Key Takeaways:

The global Autism Spectrum Disorder Therapeutics Market is expected to exhibit a CAGR of 6.1 % during the forecast period due to rising research and survey regarding the safety of the autism drug in patients. For instance, in March 2022, Stalicla effectively finished phase 1b trials of medicine candidate STP1 and there were positive outcomes with decreasing symptoms in patients with Autism Spectrum Disorder.

Among regions North America, Asia Pacific, and Europe are anticipated to witness robust growth in the global Autism Spectrum Disorder Therapeutics Market owing to the rising prevalence of Autism Spectrum Disorder, increasing R&D, rising collaborations, and partnerships. For instance, as per Zynerba Pharmaceuticals, in November 2022, over 1.4 million were suffering from Autism Spectrum Disorder in U.S.